Skip to main content

Table 1 Baseline patient data

From: Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study

Patient ID

Gender

Ethnicity

Biopsy result

Urine PCR, mg/mmol

Serum albumin, g/L

Treatment, daily dose in mg

LN1

Female

Asian

III

58

38

P (20), H (400)

LN2

Female

White

IV, V

457

30

P (20), MPa

LN3

Female

Black

V

123

28

P (30), H (400)

LN4

Female

White

IV

533

21

P (10), H (400), MMF (1,500)

LN5

Female

White

V

569

23

P (10), H (400)

LN6

Female

Black

III

202

30

P (5), Ca

LN7

Female

Asian

III

96

20

P (15), A (100)

LN8

Female

Asian

III/V

208

36

P (12.5), H (200)

LN9

Female

Asian

III

34

28

P (60), Ca

LN10

Female

Asian

IV

66

44

P (10), MMF (2,000)

LN11

Male

Asian

IV

1,017

17

P (20), M (1,000), Ca

LN12

Female

White

II

312

34

H (400)

LN13

Female

White

II

127

33

H (400), MPa

LN14

Female

White

V

366

34

P (20), A (100)

LN15

Female

White

III/V

88

43

P (5), A (100)

LN16

Female

Black

IV/V

297

37

P (20)

  1. aMP and C signify a recent intravenous pulse of methylprednisolone or cyclophosphamide, respectively; thus, there is no value for daily dose. Values for daily dose of each drug refer to the dose being taken at the time of entry into the study. A, azathioprine; H, hydroxychloroquine; LN, lupus nephritis; MMF, mycophenolate mofetil; P, prednisolone; PCR, protein/creatinine ratio.